Publications

Candida famata as a Cause of Invasive Candidiasis: Misidentification in Two Global Surveillance Systems, Lead author: Castanheira M, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Contemporary Potencies of Minocycline (MIN) and Tetracycline (TET) Tested Against Gram-positive Pathogens: SENTRY Program Results using CLSI and EUCAST Breakpoint Criteria, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Influence of Surfactant (Polysorbate-80) on Susceptibility Testing Results for the Polymyxins Using Broth Microdilution Methods, Lead author: Sader HS, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Educational Susceptibility (S) Testing as a Critical Component of Laboratory Proficiency Programs: American Proficiency Institute (API) Results for 2007-2010, Lead author: Jones RN, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Outbreak of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals: Report from the SENTRY Antimicrobial Surveillance Program, Lead author: Mendes RE, presented at 112th annual American Society for Microbiology General Meeting (ASM), June 16 – 19, 2012, San Francisco, CA

Antimicrobial Activity of the New Cephalosporin Ceftaroline Tested Against Bacterial Isolates FromSurgical Skin and Skin Structure Infections in USA Medical Centers (2008-2011), Lead author: Sader HS, presented at 32nd annual Surgical Infection Society (SIS), April 18 – 21, 2012, Dallas, Texas

Transferable Plasmid-Mediated Resistance to Linezolid Due to cfr in a Human Clinical Isolate of Enterococcus faecalis, Lead author: Diaz, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Macrolide and tetracycline resistance in Moraxella catarrhalis isolates from 2009-2011 is higher in the Asia Pacific Region than in other regions of the world, Lead author: Flamm R, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Report of linezolid resistance from the Zyvox® Annual Appraisal of Potency and Spectrum programme (Europe, Latin America, Asia Pacific), Lead author: Flamm R, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial susceptibility and species identification of Corynebacterium spp. strains collected in Europe and USA medical centres, 2006-2010, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Frequency and antimicrobial resistance of Gram-negative bacilli isolated from Latin America hospitals: results from SENTRY Antimicrobial Surveillance programme, 2008-2010, Lead author: Gales AC, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity and spectrum of antimicrobial coverage against pathogens collected from patients with hospital-acquired and ventilated-associated bacterial pneumonia in USA medical centres, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Resistance phenotypes observed from amongst Staphylococcus aureus and pneumococci isolated from USA paediatric patients during the 2009 AWARE surveillance programme, Lead author: Krause, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Vancomycin MICs compared between MRSA and MSSA in 9 countries, Lead author: Reynolds, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Retrospective search for NDM-1 reveals Indian origin of DIM-1 metallo-betalactamase, Lead author: Castanheira M, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Characterisation of two new variants of 16S rRNA methylase encoding genes, rmtB2 and rmtB3, Lead author: Castanheira M, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Genotypic and phenotypic characterisation of methicillin-resistant Staphylococcus aureus strains recovered from a phase IV clinical trial for linezolid versus vancomycin for the treatment of nosocomial pneumonia, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

More potency assay results for EX-USA generic piperacillin/tazobactam lots and initial meropenem generic lots marketed in the USA, Lead author: Jones RN, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of JNJ-Q2, a new fluoroquinolone, tested against contemporary (2011) acute bacterial skin and skin-structure infection pathogens from Europe, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of ceftaroline/avibactam tested against multidrug-resistant Enterobacteriaceae and methicillin-resistant Staphylococcus aureus collected from USA hospitals in 2011, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial spectrum and potency of ceftaroline/avibactam when tested against bacterial isolates from complicated urinary tract infections in the United States, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of the novel antimicrobial ceftolozane/tazobactam (CXA-201) tested against contemporary clinical strains from European hospitals, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of PTK 0796 (omadacycline) and comparator agents against contemporary pathogens commonly associated with community-acquired respiratory tract infections collected during 2011 from the European Union, Lead author: Flamm R, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of PTK 0796 (omadacycline) tested against Gram-positive organisms isolated from European hospitals in 2011, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

In vitro evaluation of antimicrobial spectrum and determination of optimal MIC test conditions for the novel protein epitope mimetics antibiotic POL7080, Lead author: Dale, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Spectrum and potency of ceftaroline against leading pathogens causing skin and skin-structure infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Ceftaroline activity against clinical isolates from United States hospitals: results from the 2011 Assessing Worldwide Antimicrobial Resistance Evaluation programme, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Spectrum and potency of ceftaroline against leading pathogens causing community acquired respiratory tract infections in Europe and South Africa, 2010, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Streptococcus pneumoniae from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Characterisation of resistance mechanisms and epidemiology of Enterobacteriaceae collected during a phase II clinical trial for ceftazidime avibactam, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Prevalence of ESBL and carbapenemase-producing phenotypes of Enterobacteriaceae identified in the 2010 AWARE surveillance programme, Lead author: Krause, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Occurrence and genetic analysis of OXA-48-producing strains in European countries, 2007-2010, Lead author: Castanheira M, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of ceftaroline tested against methicillin-resistant Staphylococcus aureus clones from Australia and New Zealand, 2010, Lead author: Bell JM, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Antimicrobial activity of ceftaroline and comparator agents against contemporary (2010) Staphylococcus aureus isolates from Europe and South Africa, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Oritavancin activity tested against Staphylococcus aureus responsible for documented infections in European hospitals, Lead author: Mendes RE, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Update on daptomycin activity and spectrum tested against Gram-positive organisms collected in 2011 from European medical centres, Lead author: Sader HS, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of JNJ-Q2 against Staphylococcus aureus isolated from patients with acute bacterial skin and skin structure infection obtained during a phase II clinical trial, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Adjusting EUCAST zone diameter breakpoints for Haemophilus influenzae on the Mueller-Hinton Fastidious media, Lead author: Ahman, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Contemporary doxycyline and tetracycline susceptibility testing using CLSI and EUCAST criteria for Gram-positive pathogens: results from SENTRY programme, Lead author: Jones RN, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Activity of moxifloxacin tested against 14,930 clinical isolates of Enterobacteriaceae from Europe, Lead author: Farrell DJ, presented at 22nd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), March 31 – April 3, 2012, London, UK

Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. by Pfaller MA, Espinel-Ingroff A, Castanheira M, Cuenca-Estrella M, Diekema DJ, Fothergill A, Faller J, Ghannoum M, Jones RN, Lockhart SR, Ostrosky-Zeichner L and Pelaez T published in J. Clin. Microbiol. 2012; 50 (6): 2040-2046

Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. by Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA and Jones RN published in J. Clin. Microbiol. 2012; 50 (4): 1199-1203

Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. by Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, and Turnidge J published in Antimicrob. Agents Chemother. 2012; 56 (6): 3107-3113

Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010. by Mendes RE, Woosley LN, Farrell DJ, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1639-1642

Telavancin activity tested against a contemporary collection of Gram-positive pathogens from USA hospitals (2007-2009). by Mendes RE, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 72 (1): 113-117

Pharmacodynamics of beta-lactamase inhibition by NXL104 in combination with ceftaroline, examining organisms with multiple types of beta-lactamases. by Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R and Drusano GL published in Antimicrob. Agents Chemother. 2012; 56 (1): 258-270

Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus. by Fernandez J, Abbanat D, Shang W, He W, Amsler K, Hastings J, Queenan AM, Melton JL, Barron AM, Flamm RK and Lynch AS published in Antimicrob. Agents Chemother. 2012; 56 (3): 1476-1484

Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: Report of the SENTRY antimicrobial surveillance program. by Castanheira M, Costello AJ, Deshpande LM and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (3): 1668-1669

Evaluation of quinolone resistance-determining region mutations and efflux pump expression in Neisseria meningitidis resistant to fluoroquinolones. by Castanheira M, Deshpande LM, Jones RN and Farrell DJ published in Diagn. Microbiol. Infect. Dis. 2012; 72 (3): 263-266

Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. by Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2012; 56 (1): 352-357